Dems' $100B deal reduced further: Medicare drug price negotiations pushed to 13 years for biologics
House Democrats are on the cusp of passing two major pieces of Biden’s agenda Friday, but Medicare drug price negotiations — once the centerpiece of the Build Back Better Act’s revenue stream — has been relegated to only about $100 billion in savings over the next decade. That number fell lower yesterday.
Overall, the compromise ended up winning over both Democrat senators receiving PhRMA cash, like Kyrsten Sinema and Bob Menendez, and more liberal senators, like Elizabeth Warren. But on the House side, the battle continued up until yesterday evening.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
